261 related articles for article (PubMed ID: 9795096)
1. Inhibition of hippocampal acetylcholine release after acute and repeated Delta9-tetrahydrocannabinol in rats.
Carta G; Nava F; Gessa GL
Brain Res; 1998 Oct; 809(1):1-4. PubMed ID: 9795096
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A.
Gessa GL; Casu MA; Carta G; Mascia MS
Eur J Pharmacol; 1998 Aug; 355(2-3):119-24. PubMed ID: 9760025
[TBL] [Abstract][Full Text] [Related]
3. Delta9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study.
Acquas E; Pisanu A; Marrocu P; Goldberg SR; Di Chiara G
Eur J Pharmacol; 2001 May; 419(2-3):155-61. PubMed ID: 11426837
[TBL] [Abstract][Full Text] [Related]
4. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol.
Tanda G; Loddo P; Di Chiara G
Eur J Pharmacol; 1999 Jul; 376(1-2):23-6. PubMed ID: 10440085
[TBL] [Abstract][Full Text] [Related]
5. Effects of SR141716A on diazepam substitution for delta9-tetrahydrocannabinol in rat drug discrimination.
Wiley JL; Martin BR
Pharmacol Biochem Behav; 1999 Nov; 64(3):519-22. PubMed ID: 10548265
[TBL] [Abstract][Full Text] [Related]
6. Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics.
Fernández-Ruiz JJ; Muñoz RM; Romero J; Villanua MA; Makriyannis A; Ramos JA
Biochem Pharmacol; 1997 Jun; 53(12):1919-27. PubMed ID: 9256167
[TBL] [Abstract][Full Text] [Related]
7. Delta9-THC induced hyperphagia and tolerance assessment: interactions between the CB1 receptor agonist delta9-THC and the CB1 receptor antagonist SR-141716 (rimonabant) in rats.
Järbe TU; DiPatrizio NV
Behav Pharmacol; 2005 Sep; 16(5-6):373-80. PubMed ID: 16148441
[TBL] [Abstract][Full Text] [Related]
8. delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors.
French ED
Neurosci Lett; 1997 May; 226(3):159-62. PubMed ID: 9175591
[TBL] [Abstract][Full Text] [Related]
9. Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation.
Hoffman AF; Oz M; Yang R; Lichtman AH; Lupica CR
Learn Mem; 2007; 14(1-2):63-74. PubMed ID: 17202425
[TBL] [Abstract][Full Text] [Related]
10. Effects of chronic Delta(9)-tetrahydrocannabinol treatment on hippocampal extracellular acetylcholine concentration and alternation performance in the T-maze.
Nava F; Carta G; Colombo G; Gessa GL
Neuropharmacology; 2001 Sep; 41(3):392-9. PubMed ID: 11522331
[TBL] [Abstract][Full Text] [Related]
11. Local administration of delta9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action.
Ko MC; Woods JH
Psychopharmacology (Berl); 1999 Apr; 143(3):322-6. PubMed ID: 10353438
[TBL] [Abstract][Full Text] [Related]
12. (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide.
Järbe TU; Lamb RJ; Lin S; Makriyannis A
Psychopharmacology (Berl); 2001 Aug; 156(4):369-80. PubMed ID: 11498713
[TBL] [Abstract][Full Text] [Related]
13. Modulation by fluoxetine of striatal dopamine release following Delta9-tetrahydrocannabinol: a microdialysis study in conscious rats.
Malone DT; Taylor DA
Br J Pharmacol; 1999 Sep; 128(1):21-6. PubMed ID: 10498830
[TBL] [Abstract][Full Text] [Related]
14. Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for cannabinoid addiction.
Dhawan K; Kumar S; Sharma A
J Pharm Pharmacol; 2002 Jun; 54(6):875-81. PubMed ID: 12079005
[TBL] [Abstract][Full Text] [Related]
15. Effects of long-term exposure to delta9-THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions.
Zhuang S; Kittler J; Grigorenko EV; Kirby MT; Sim LJ; Hampson RE; Childers SR; Deadwyler SA
Brain Res Mol Brain Res; 1998 Nov; 62(2):141-9. PubMed ID: 9813289
[TBL] [Abstract][Full Text] [Related]
16. Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors.
Petitet F; Jeantaud B; Reibaud M; Imperato A; Dubroeucq MC
Life Sci; 1998; 63(1):PL1-6. PubMed ID: 9667767
[TBL] [Abstract][Full Text] [Related]
17. Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions.
Romero J; Garcia-Palomero E; Castro JG; Garcia-Gil L; Ramos JA; Fernandez-Ruiz JJ
Brain Res Mol Brain Res; 1997 Jun; 46(1-2):100-8. PubMed ID: 9191083
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoid CB(1) receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo.
Acquas E; Pisanu A; Marrocu P; Di Chiara G
Eur J Pharmacol; 2000 Aug; 401(2):179-85. PubMed ID: 10924924
[TBL] [Abstract][Full Text] [Related]
19. Two distinctive antinociceptive systems in rats with pathological pain.
Mao J; Price DD; Lu J; Keniston L; Mayer DJ
Neurosci Lett; 2000 Feb; 280(1):13-6. PubMed ID: 10696800
[TBL] [Abstract][Full Text] [Related]
20. Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol.
Romero J; Berrendero F; Manzanares J; Pérez A; Corchero J; Fuentes JA; Fernández-Ruiz JJ; Ramos JA
Synapse; 1998 Nov; 30(3):298-308. PubMed ID: 9776133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
